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Abstract
To aid preclinical development of novel therapeutics for myeloma, an in vivo model which recapitulates the human
condition is required. An important feature of such a model is the interaction of myeloma cells with the bone marrow
microenvironment, as this interaction modulates tumour activity and protects against drug-induced apoptosis. Therefore
NOD/SCIDccnull mice were injected intra-tibially with luciferase-tagged myeloma cells. Disease progression was monitored
by weekly bioluminescent imaging (BLI) and measurement of paraprotein levels. Results were compared with magnetic
resonance imaging (MRI) and histology. Assessment of model suitability for preclinical drug testing was investigated using
bortezomib, melphalan and two novel agents. Cells engrafted at week 3, with a significant increase in BLI radiance occurring
between weeks 5 and 7. This was accompanied by an increase in paraprotein secretion, MRI-derived tumour volume and
CD138 positive cells within the bone marrow. Treatment with known anti-myeloma agents or novel agents significantly
attenuated the increase in all disease markers. In addition, intra-tibial implantation of primary patient plasma cells resulted
in development of myeloma within bone marrow. In conclusion, using both myeloma cell lines and primary patient cells, we
have developed a model which recapitulates human myeloma by ensuring the key interaction of tumour cells with the
microenvironment.
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Introduction
Multiple myeloma is caused by clonal expansion of malignant
plasma cells within the bone marrow. Acquired genetic mutations
within myeloma cells and their interaction with bone marrow
stromal cells (BMSCs) contribute to disease progression and drug
resistance [1]. Myeloma cells and BMSCs quickly become
mutually dependent on one another through a set of feedback
loops comprised of various secreted cytokines and growth factors.
This leads to dysregulation of key processes contributing to
enhanced drug resistance.
An animal model that accurately reflects human myeloma and
takes into account the protective nature of BMSCs would be
powerful in confirming the efficacy of therapeutic agents in vivo,
and accelerate the drug development process. A number of
different animal models are currently used to study myeloma,
including 5TMM, together with various SCID xenografts, and
transgenic models [2–11]. Although these models have been useful
in highlighting the importance of certain genetic events and
signalling pathways in myeloma, they have a number of
limitations. These include the use of mouse, rather than human,
myeloma cells, a lack of tumour homing and interaction within the
bone marrow, the presence of extramedullary disease particularly
in the lungs, spleen and liver (areas not affected in patients), and a
long latency period before disease establishment.
We believe the ideal model to test novel agents in a preclinical
setting should possess the following characteristics; 1) the disease
should be representative of the human condition, 2) there should
be a relatively quick time to progression from initial inoculation,
and 3) there should be markers to monitor the disease during
treatment.
In order to address the limitations of these previous models, we
report an adapted version of a model set up in AML [12] for the
study of myeloma development and treatment. In this model we
have shown successful engraftment of human myeloma cell lines
and primary human material directly into the bone marrow of
mice. The progression of the resulting tumours were tracked using
bioluminescent imaging (BLI) and validated with a series of
techniques including serum paraprotein measurement (ELISA),
magnetic resonance imaging (MRI), flow cytometric analysis of
CD138 expression and histology. Furthermore, we show that this
model is suitable for the assessment of response to therapy with
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drugs known to be efficacious against myeloma, bortezomib (BZB),
and melphalan, and two novel agents, an aminopeptidase inhibitor
and a HDAC inhibitor which we have previously shown to be
effective in vitro, and which has recently shown efficacy in a phase
I/II trial in acute myeloid leukaemia and myeloma [13,14].
Materials and Methods
Procedures involving animals were approved by the Home
Office and carried out within guidelines set out by both the
Institute of Cancer Research’s Animal Ethics Committee and
national guidelines according to the United Kingdom Coordinat-
ing Committee on Cancer Research [15].
Cell Lines, Patient Cells and Reagents
U266 myeloma cells (ATCC) were transfected pcDNA3.1luciferase
(a kind gift from Gary Box, ICR) using AmaxaH NucleofectorH Kit
C (Lonza), according to the manufacturer’s protocol. Following
nucleofection, cells were cultured in RPMI-1640 GlutaMAXTM
medium (Invitrogen) (supplemented with 10% heat inactivated
foetal calf serum, 60 mg/ml penicillin, and 100 mg/ml streptomycin)
and G418 (Invitrogen; 2 mg/ml). Tosedostat and CHR-3996 were
acquired from Chroma Therapeutics Ltd. Stock solutions were
made in 100%DMSO and stored at -20uC.Working solutions were
made by dilution with phosphate buffered saline (PBS; Invitrogen).
Bortezomib (BZB) was obtained from Johnson & Johnson and
reconstituted in 0.9% w/v saline. Once reconstituted, BZB was
administered within 2–3 hours and discarded afterward. Melphalan
(Sigma) was dissolved in ethanoic acid and diluted with PBS for
administration.
Intra-tibial inoculation of tumour cells
Female NOD/SCIDccnull mice (The Jackson Laboratory, USA)
approximately 6 weeks old were anaesthetized using Hypnorm/
Hypnovel/water in a ratio of 1:1:3. Mice were inoculated via
intra-osseus injection in the tibia with either 16105 or 26106
U266luciferase myeloma cells in 20 mL RPMI-1640. Mice were
monitored for myeloma progression over 8–10 weeks by weekly
bioluminescent imaging (BLI) and paraprotein level measurement.
Peripheral blood was taken from 3 plasma cell leukaemia
patients and plasma cells were extracted by Ficoll-Paque. To assess
the engraftment of patient cells, mice were inoculated with either
16105, 16106 or 16107 cells in 20 mL complete RPMI-1640
GlutaMAXTM medium. Mice were monitored for myeloma over 5
months. Post-mortem flow cytometry was used to assess tumour
infiltration.
Treatment schedules
Mice injected with U266luciferase cells were assigned into the
following three treatment groups: no treatment control (n = 6),
0.8 mg/kg BZB I.P. (n = 9), and 75 mg/kg tosedostat I.P. (n = 9).
In addition a negative control group of mice that were not injected
with cells and did not receive treatment was included. Treatment
commenced 5 weeks after tumour cell inoculation and continued
for 4 weeks. Tosedostat treatment was maintained for 6 days out of
7 each week. BZB was administered twice weekly.
In vivo bioluminescence imaging
Mice were imaged at weeks 4 and 9 post-inoculation in order to
assess tumour burden pre- and post-therapy. Mice were anaes-
thetized using isoflurane and imaged 9 minutes after I.P. injection
of D-luciferin (1.5 mg/mouse, Caliper Life Sciences). Using an
IVISH Imaging System 200 Series (Xenogen), images were
acquired by 60 second exposure. Luciferase signal intensity was
quantified by measuring average radiance (p/s/cm2/sr) using
Living Image 4.0 software.
Measurement of serum paraprotein levels
Serum samples were acquired from each mouse by tailbleed for
the measurement of human Igl in murine serum using enzyme
linked immunosorbent assay (Human Lambda ELISA Kit; Bethyl
Laboratories Inc). The assay was carried out as per the
manufacturer’s protocol.
Magnetic Resonance Imaging (MRI)
MRI scans were acquired on a 7T horizontal bore Bruker
system. Mice were anesthetized using Hypnorm/Hypnovel/water
(1:1:3), restrained with dental paste to limit motion artefacts, and
positioned supine within a 3 cm birdcage 1H coil. T2-weighted
TurboRARE images were acquired using TE=24.6 ms,
TR=6000 ms, coronal slice thickness 0.3 mm, FOV
30630 mm, matrix 1006100, 16 averages, AQ ,14 min. On
these T2-weighted images, tumour was identified as a hyperintense
signal enclosed within the cortical bone. Tumour burden was
quantified from regions of interest drawn on the periphery of the
hyperintense signal in OsiriX and followed through each slice, for
each bone within both legs.
Flow cytometry & histology
Bone and tissue samples were collected, homogenized and
stained with anti-CD138-APC antibody (BD Biosciences) to
identify the presence of human myeloma cells, according to the
manufacturer’s protocol. Stained samples were then analyzed
using an LSRII flow cytometer (BD Biosciences) and FACSDiva
Software. Bones (tibia and femur) were excised for histological
examination and fixed in neutral buffered formaldehyde (10%)
overnight at 4uC. Samples were washed with water and decalcified
in 10% EDTA (pH7.4) for 14 days, until they lost normal
structural rigidity. The bones were then embedded in paraffin
bocks and 5 mm sections cut. Sections were subsequently stained
with haematoxylin and eosin (H&E), and immunohistochemically
processed using anti-CD138 antibodies, and evaluated by histo-
pathology. Sections were visualized and recorded on a BX51
microscope (Olympus Optical Co. Ltd, UK) equipped with a
driveable stage (Prior Scientific Instruments, UK), using CellP
software (Soft Imaging System, Germany).
Statistical analysis
All data are presented as mean 6 SEM. Statistical analysis was
conducted using either 1-way or 2-way ANOVA with Bonferroni
post-test, unless stated otherwise in the text. GraphPad Prism 5.01
software was used for these analyses.
Results
Optimization of cell number
Initial experiments were conducted in order to optimize the cell
number for implantation. Time to hind limb paralysis and Igl
levels were monitored. Mice were injected intra-tibially with either
16105 (cohort A) or 26106 (cohort B) U266luciferase cells. Over the
next 8 weeks, blood samples were collected in order to examine
serum levels of human Igl. Paraprotein levels in cohort A did not
increase until week 5, compared to week 3 in cohort B. By week 8,
cohort B had high levels of Igl at 2998.7 6 247.6 ng/ml,
compared to 1278.3 6 20.9 ng/ml in cohort A (Figure S1). In
both cohorts, post-mortem examination revealed severe spinal
deformity plus no organ involvement, both representative of
human myeloma pathogenesis and progression. From these results
Clinically Relevant Mouse Model of Myeloma
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it was decided that 26106 cells would be used to inoculate animals
given the shortened lag time to development of myeloma.
Engraftment and growth of U266luciferase cells in NOD/
SCID-c IL2R-/- mice monitored by bioluminescence
imaging (BLI)
Engraftment of U266luciferase was first observed approximately 3
weeks post-inoculation (Fig 1A). BLI acquired at weeks 6–8
revealed spread to the pelvis, contralateral femur, tibia and spine.
The endpoint of the experiment was reached at weeks 8–9 when
animals developed hind limb paralysis. Quantitative BLI mea-
surements were used to construct growth curves which corre-
sponded to tumour load (Fig 1B). BLI showed a significant
increase in radiance from 5.66105 to 43.06105 p/s/cm2/sr
between weeks 5 and 7 (p,0.001, 2-way ANOVA with Bonferroni
post-test).
Validation of bioluminescence imaging: serum
paraprotein levels and MRI
Serum paraprotein levels were measured by ELISA in parallel
with BLI (Fig 1C). In correlation with initial engraftment at week
3, there was a corresponding increase in Igl levels. Serum levels of
Igl increased from 149.3 to 4152.1 ng/ml during weeks 3–9
(p,0.05). MRI images acquired at weeks 4 and 8 showed a
significant increase in intra-bone signal intensity, from 6.4 to
27.6 mm3 (p,0.05, Student’s paired t-test). These data confirm
the changes seen in BLI.
Validation of bioluminescence imaging: CD138
expression & histology
Analysis by flow cytometry, post-mortem, confirmed the
presence of CD138 expressing human myeloma cells in the bone
environment and the absence of CD138 expression from all organs
(Fig 2A). Following injection of cells into the tibia, tumour cells
were seen in the femur, contralateral tibia and femur as well as the
spine. This was confirmed by histological samples. Fig 2B shows
the staining of U266luciferase cells with haematoxylin/eosin, in the
tibia and femur. Results from histology correlated with the results
from flow cytometry. Results from this pilot study confirm that
injection of human myeloma cells directly into the bone of NOD/
SCIDccnull mice results in disease characteristics similar to those
observed in patients with an increase in paraprotein levels, disease
Figure 1. Engraftment and growth of U266luciferase cells as monitored by BLI, serum paraprotein and MRI. A. (i) Dorsal and (ii) ventral
BLI acquired from IVIS over weeks 3–7 post-inoculation. B. Quantitative measurement of radiance from BLI. Radiance reflects the intensity of
luciferase luminescence and therefore number of luciferase-tagged cells present. Results show that radiance increases in a time-dependent manner
over the course of the experiment and that a significant increase in radiance occurs over weeks 5–7 (p,0.05, 1-way ANOVA with Bonferroni post-
test). C. Paraprotein levels in the serum increases in a time dependent manner and correlates with the increase seen in BLI. MRI-derived tumour
volumes determined at approximately weeks 5 and 10 confirmed tumour progression seen with BLI.
doi:10.1371/journal.pone.0057641.g001
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confined to the bone marrow, spinal progression and eventual
paralysis.
Adaptation of model for primary patient material
In order to determine whether the direct delivery of tumour
cells to the bone marrow could also result in the growth of patient
primary cells, 10 mice received intra-tibial inoculation of material
from 3 cases of plasma cell leukaemia with complex cytogenetics.
Mice were inoculated with either 16105, 16106 or 16107
CD138+ cells in 20 mL complete RPMI-1640 GlutaMAXTM
medium and monitored for signs of myeloma development,
including hind limb paralysis, over a period of 6 months. Mobility
issues developed in 6 mice injected with 16106 and 16107 cells,
from all 3 donors (2 with additional plasmacytoma localized at the
injection site). Flow cytometry demonstrated confinement to the
bone marrow (Figure S2). Even with small numbers, a correlation
between lag time and cell dose was apparent (data not shown). The
ability of the mice models to support the growth of patient cells is
unusual and highlights the importance of the direct intra-tibial
injection route in allowing the myeloma cell:BMSC interaction.
The intra-tibial model of myeloma bone disease can be
used to monitor drug response
Having demonstrated the development of a suitable preclinical
mouse model and strategy to track the progression of myeloma, we
then investigated its suitability in testing anti-myeloma therapies,
specifically the effective myeloma therapeutic, bortezomib (BZB),
and a novel aminopeptidase inhibitor, tosedostat. Tosedostat has
previously been shown to inhibit cell proliferation, induce cell
cycle arrest and apoptosis in myeloma cells in vitro.13 Therapy was
divided into 3 groups; BZB treated, tosedostat treated and positive
control. An additional group of non-inoculated mice was used as a
negative control. At the beginning of the treatment schedule
(Week 5), each group of mice displayed similar BLI radiance and
paraprotein levels (Fig 3A & 3B). At the end of the 4 week
treatment schedule, BLI was performed again. In the control
group, there was a significant increase in radiance from 16.1 6
4.26105 p/s/cm2/sr to 69.0 6 24.46105 p/s/cm2/sr (p = 0.01
students t-test). In comparison, in the BZB and tosedostat
treatment groups, no significant increase in radiance was seen
(BZB: 5.2 6 1.16105 p/s/cm2/sr to 1.1 6 0.66105 p/s/cm2/sr;
tosedostat: 9.9 6 3.26105 p/s/cm2/sr to 13.8 6 4.76105 p/s/
Figure 2. CD138 expression and histology validate BLI, paraprotein and MRI results. A. Flow cytometry histograms show the presence of
CD138+ cells in the tibia, femur and spine of myeloma mice. Cytometric evaluation of the organs confirmed that the cells were confined to the bone
marrow. B. Histological analysis of the tibia and femur confirmed the presence of a high number of CD138+ plasma cells (green arrows), resulting in
the loss of classical bone marrow architecture.
doi:10.1371/journal.pone.0057641.g002
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cm2/sr). This effect was also seen using another standard anti-
myeloma agent, melphalan and a novel histone deacetylase
inhibitor CHR-3996 (Figure S3). BLI imaging of negative control
mice did not reveal luciferase activity.
Paraprotein levels mimicked these changes in BLI (Fig 3C).
Serum Igl levels diverged at week 6 with BZB mice displaying the
lowest level at 49.0 6 19.6 ng/ml, which was significantly
different from control, at 948.4 6 255.9 ng/ml (p,0.01, 2-way
ANOVA with Bonferroni post-test). Tosedostat treated mice also
had significantly lower Igl levels than control, at 191.0 6
46.9 ng/ml (p,0.01, 2-way ANOVA with Bonferroni post-test).
By the end of treatment, Igl levels in control, BZB and tosedostat
treated mice were 2473.7 6 211.7, 132.5 6 50.8 and 923.0 6
248.6 ng/ml, respectively. Igl levels in both treatment groups
were highly significantly different from control (p,0.001, 2-way
ANOVA with Bonferroni post-test). Again this effect was also seen
using melphalan and CHR-3996 (Figure S3).
Flow cytometry showed a significant reduction in CD138+
human myeloma cells in both tibias and spine in BZB and
tosedostat treated mice compared to positive control mice
(p,0.001) indicating decreased myeloma cell number (Fig 4A).
Histological staining of paraffin embedded samples confirmed the
observation made by flow cytometry (Fig 4B).
MRI was used to determine the intra-bone tumour volume in
each treatment group. Average tumour volumes were as follows:
BZB group 14.7 6 1.0 mm3, tosedostat group 23.5 6 1.8 mm3
and positive control group 32.8 6 0.9 mm3. Tumour volume for
both treatment groups was significantly different from positive
control (p,0.001, 1-way ANOVA with Bonferroni post-test). In
addition, tumour volume for the bortezomib treated group was not
significantly different from negative control mice (11.1 6
0.8 mm3). (Fig 5). Furthermore, MRI images of the tibia and
femur clearly demonstrate that BZB treatment significantly
reduced the signal intensity compared to control and to a greater
degree than tosedostat. The results gained from MRI correlate
well with Igl paraprotein levels, BLI, CD138 expression and
histology.
These data show that this model is clinically representative of
human myeloma development and progression, has a short latency
to development and possesses various chemo-sensitive markers
that can be used to monitor response to therapeutics i.e. MRI,
BLI, paraprotein and the presence of CD138+ myeloma cells.
These characteristics fulfil the criteria specified above for an ideal
in vivo model of myeloma suitable for drug evaluation.
Figure 3. BLI and serum paraprotein changes in response to therapy. A. (i) Pre-treatment and (ii) post-treatment BLI of mice at weeks 5 and
9. B. Quantitative measurement of radiance from BLI. (i) No significant difference in radiance between treatment groups was seen at the start of the
treatment schedule. (ii) Post-treatment radiance levels revealed a significant attenuation of tumour spread by both BZB and tosedostat (p,0.05, 1-
way ANOVA with Bonferroni post-test). C. Paraprotein levels during treatment schedule. Positive control mice showed an exponential increase in
serum levels of Igl over 9 weeks. In comparison, both treatment groups did not exhibit the same increase, with significantly lower levels by the end
of treatment (p,0.05).
doi:10.1371/journal.pone.0057641.g003
Clinically Relevant Mouse Model of Myeloma
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Discussion
The development of a representative model of human myeloma
for preclinical assessment of novel therapeutic agents is an
important aim. In this study we present a novel, reproducible
model of human myeloma that fulfils these criteria. The model was
established by intra-tibial implantation of luciferase transduced
U266 myeloma cells, into NOD/SCIDccnull mice, and was
confirmed using primary patient cells. The resulting tumours
exhibited phenotypic, dissemination and growth patterns highly
similar to those of human myeloma. Tumour engraftment was
observed 3 weeks post-inoculation by BLI, with concomitant
elevation of serum Igl levels. The presence of tumour cells in the
bone marrow environment was confirmed by examination of
CD138 expression, MRI and histology. We then sought to
evaluate its suitability for preclinical testing of novel myeloma
therapeutics. Bortezomib and melphalan were used due their
clinical success as therapy for myeloma. In addition tosedostat, a
novel aminopeptidase inhibitor and CHR-3996, a HDAC
inhibitor which have previously shown efficacy against myeloma
cells in vitro. All therapies caused reductions in tumour load and
associated myeloma markers.
There are a number of reasons why this model is superior to
existing models and, therefore, provides an appropriate setting for
therapeutic testing. A summary of existing in vivo models of
myeloma suitable for drug evaluation can be found in Table 1.
The 5TMM model was developed in 1979 after it was found that
aging C57BL/KalwRij mice spontaneously developed myeloma
[2]. Serial transplants using these murine myeloma cells were then
conducted to create a syngeneic myeloma model. Recipients
exhibit localization of myeloma cells to the bone marrow,
increased paraprotein secretion and bone disease. Despite these
features being common between murine and human myeloma,
this model is limited by being solely murine-derived, and
representative of only one type of myeloma. The NOD/
SCIDccnull model described herein is based on the implantation
Figure 4. CD138 expression changes in response to therapy. A. Percentage of CD138+ human myeloma cells measured by flow cytometry in
bone aspirates of mice (n = 3), showing a significantly lower percentage of positive cells in both tibias and spine of mice in the two treatment groups
than in untreated mice (p,0.05, 2-way ANOVA with Bonferroni post-test). No CD138+ cells were observed in the organs of any of the mice. B.
Histological analysis of sections from the tibias of mice from each group showed distinct differences. (i) Sections from healthy mice displayed classical
architecture, with no CD138+ cells. (ii) In comparison, sections from untreated myeloma mice showed a high infiltration of CD138+ cells with loss of
normal architecture. (iii) Treatment of mice with BZB resulted in the return of normal architecture and loss of CD138+ cells. (iv) A similar result was
observed in mice treated with tosedostat, but with occasional scattered CD138+ cells.
doi:10.1371/journal.pone.0057641.g004
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of human myeloma cells, which allows for different human
myeloma subtypes to be investigated e.g. myeloma cells possessing
different genetic backgrounds or with inherent resistance to a
specific therapy. Additionally, engraftment of human cells is more
relevant for investigating therapeutic targets and preclinical
therapeutic testing, than murine myeloma cells.
The plasmacytoma model [3] produced by the injection of
pristane oil into the peritoneum of Balb/c mice also has a number
of limitations. Unlike myeloma, chemically induced plasmacyto-
mas remain localized to the site of injection, do not produce bone
lesions and do not rely on the host bone marrow microenviron-
ment [16]. Furthermore, this model has a significant lag time
(approx 120 days to development of ascites), and even then has
variable incidence (,60%).
Xenograft models are a popular choice for recreating myeloma
in mice due to the speed of production and efficiency of
engraftment. In subcutaneous xenograft models, cells are mixed
with matrigel and injected into mice to form palpable tumours
[17]. This route of administration means that tumours are
localized and do not resemble the pattern of growth seen in
human myeloma. In addition, this model does not take into
account interactions with the bone marrow microenvironment,
Figure 5. MRI changes in response to therapy. MRI-derived tumour volumes. A. Tumour was identified as a hyperintense signal enclosed within
the cortical bone on T2-weighted images. MRI images showed a reduction in signal intensity in both treatment groups compared to positive control
in both the tibia (T) and femur (F). B. Tumour volume was quantified from regions of interest drawn on the periphery of the hyperintense signal. Data
are mean6 SEM, n$6. Both BZB and tosedostat (TDT) treatment resulted in a significantly lower tumour volume compared to control (p,0.05, 1-way
ANOVA with Bonferroni post-test). In addition, there was no significant difference in tumour volume between the BZB treated and negative control
group.
doi:10.1371/journal.pone.0057641.g005
Table 1. Summary of current mouse models for studying the development and treatment of myeloma.
Myeloma models Description Disadvantages
5T series Intravenous injection of cells from bone marrow
of C57Bl/KaLwRij mice showing spontaneous
development of myeloma
System is entirely murine and genetic cause of myeloma
development is unknown, therefore may not be similar to human
disease.
Chemically induced Intraperitoneal injection of pristane oil induces
cancerous proliferation of plasma cells in the
peritoneal cavity.
Lack of the following: tumor homing to the bone marrow,
dependence on the bone marrow microenvironment and generation
of osteolytic bone lesions. Therefore not characteristic of human
disease pattern.
SCID-hu/rab Myeloma cell lines/primary cells grown in
irradiated human or rabbit fetal bone chip,
which is then implanted into the mouse flank.
Ethically problematic. Fetal bone is stem cell rich, contains a high
concentration of osteoblast precursor cells, and is isolated from
general mouse physiology.
Inoculation of SCID mice with
human myeloma cells
Intravenous or subcutaneous implantation of
cells into murine host.
Lacks dependence on bone marrow microenvironment and
frequently exhibits extramedullary involvement. Model also requires
whole body irradiation pre-injection.
Transgenic models Vk*myc Does not exhibit all the important characteristic human myeloma
cytogenetic events, limited to murine malignant cells in murine
environment. Long latency to tumor development.
XBP-1
c-MAF
Intra-tibial inoculation Cells directly implanted into host bone marrow. Recapitulates human disease with myeloma confined to the bone
marrow and disease response to therapy, easily measurable using
BLI, paraprotein, MRI and histology.
doi:10.1371/journal.pone.0057641.t001
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which are vital for proliferation, survival and drug resistance.
Intravenous inoculation of myeloma cells into SCID mice has
been exploited, but results in the widespread dissemination of
myeloma to organs [18,19]. Extramedullary involvement is a
clinical characteristic of advanced myeloma but is not seen in early
developmental stages. This suggests that tumours produced by
intravenous and subcutaneous models do not rely on the bone
marrow microenvironment. Additionally, both routes require
whole body irradiation of mice prior to implantation. Two further
models, the SCID-hu and SCID-Rab, are based on the
implantation of either a human or rabbit foetal bone chip
subcutaneously, into which myeloma cells are inoculated [19].
Within this environment, myeloma cells are able to proliferate and
expand. However, this expansion is confined to the bone chip, and
does not produce the pattern of spread and growth seen in human
myeloma [4]. These features mean that pathophysiological
symptoms such as hind limb paralysis cannot be assessed. In
comparison to current xenograft models, the NOD/SCIDccnull
model described in the current paper is based on the direct
implantation of myeloma cells into the bone marrow. The key
advantages of this model are 1) these mice do not require whole
body irradiation prior to tumour cell implantation 2) there is
widespread skeletal involvement from a single inoculation site 3)
there is no evidence of extramedullary involvement as shown by
CD138 staining and histology 4) results are highly reproducible 5)
the model culminates in an observable clinical endpoint i.e. hind
limb paralysis.
It is important to consider how such a system differs from the
more complex transgenic myeloma models that have recently been
developed. Vk*myc, XBP-1 and c-MAF transgenic mice have
been shown to develop myeloma-like malignancy, with localiza-
tion of disease to bone marrow plus osteolysis [5–8]. The benefits
of transgenic mice over traditional xenograft models are that mice
are immunocompetent allowing insights into the role of immune
response. In addition therapeutic agents can be evaluated at
different stages of tumour development [9]. While these advan-
tages are desirable, there are notable disadvantages to this model.
Firstly, the tumours are murine in origin. Secondly, from a
technical aspect, transgenic models are complex to create and
there is often a long lag time to tumour development [20]. In
comparison, the model described in this paper only takes 8 weeks
from engraftment to exhibit hind limb paralysis, the end point of
myeloma.
Other model systems have also been developed for the
investigation of myeloma cell homing which could also be used
for drug evaluation [10,11]. The SCID-synth-hu model uses
polymeric subcutaneous scaffolds inoculated with human mesen-
chymal stromal cells (MSCs) with tumour cells implanted at an
external site. This model is relevant as it tackles the interaction
between tumour cells and human bone marrow milieu and can,
therefore, be used to assess preclinical agents and their effect on
tumour homing. However, it does not result in infiltration of
tumour cells into the host skeleton and is largely localized and
lacks the representative nature of disseminated disease.
The final criterion which an ideal in vivo model should fulfil is
that there should be chemo-sensitive markers to monitor during
treatment regimes. The introduction of bioluminescent tagging of
tumour cells has allowed for high-sensitivity imaging of myelo-
matic lesions in cancer models [21]. By tagging the multiple
myeloma cell line U266 with the luciferase reporter, we were able
to carry out repeated full body imaging over a period of weeks, to
indentify focal areas of luciferase activity, indicating tumour
burden. This is desirable as it is non-invasive, does not involve
radioactivity, and does not require lengthy imaging of animals
under heavy anaesthetic. The main benefit of having the luciferase
marker is the opportunity for repeated rapid screening of test
subjects in order to monitor the development of myeloma, and
response to treatment. Results from bioluminescent imaging can
then be confirmed and reinforced by examining other chemo-
sensitive markers and techniques such as CD138 expression,
histology, MRI and paraprotein levels. Results from the current set
of experiments showed that these are suitable markers in testing
the in vivo response to known myeloma therapies and newer novel
compounds.
In conclusion using both myeloma cell lines and primary patient
cells, we have developed a model which recapitulates human
myeloma with secretion of paraprotein, disease confined to the
bone marrow, lytic bone lesions and spinal compression. In
addition, we have demonstrated this model is suitable for assessing
the efficacy of both standard and novel therapeutics in vivo, using a
number of non-invasive tumour markers such as BLI and MRI.
Supporting Information
Figure S1 Optimization of cell number for implantation
into NOD/SCIDccnull mice. A. Inoculation of 16105
U266luciferase cells caused an increase in serum paraprotein at
week 5 and reached 1278.3 ng/ml by week 8. B. Inoculation of
26106 U266luciferase cells caused an increase in serum paraprotein
at week 3, and reached 2998.7 ng/ml by week 8. Mice injected
with the higher dose of cells also developed hind limb paralysis
(clinical endpoint of study) at week 8 whereas those with the lower
dose did not. On the basis of these results, it was decided to use
26106 cells for inoculation due to shortened time to disease
progression.
(TIF)
Figure S2 Adaptation of model for use with primary
cells. Flow cytometry histograms show the presence of CD138
positive cells in the bone marrow of mice inoculated with primary
patient material from 3 cases of plasma cell leukemia.
(TIF)
Figure S3 Response to additional anti-myeloma thera-
pies. Additional experiments demonstrated activity of other
known and novel therapies in the intra-tibial model. BLI and
paraprotein levels both show the efficacy of melphalan (A) and
CHR-3996 (B). Melphalan was given IP weekly (3 mg/kg) for 3
weeks and mice were sacrificed at wk7-8 due to loss of condition
from melphalan treatment. CHR-3996 was given PO 6 times per
week (50 mg/kg) for 4 weeks.
(TIF)
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